류마티스 관절염 환자에서 Mizoribine의 효과 = The effect of mizoribine on rheumatoid arthritis

다국어 초록 (Multilingual Abstract)

Background: This retrospective study was performed to investigate the clinical effects of mizoribine with using methotrexate (MTX) or mizoribine alone on those patients with rheumatoid arthritis (RA) who showed an ineffective response or intolerance to the MTX. Methods: The patients were divided into two groups: (1) combination therapy of mizoribine with MTX and (2) mizoribine alone. All the patients took 100 mg mizoribine daily for at least 16 weeks. Before and after administration of mizoribine for 16 weeks, we assessed the clinical variables such as the visual analogue pain scale (VAS), the tender joint counts (TJC), and the swollen joint counts (SJC). At each time, the laboratory parameters including the ESR, CRP, complete blood count (CBC), liver enzymes and creatinine were also measured. Disease activity scores (by the DAS28) and the adverse effects were determined at baseline and after 16 weeks. Results: Fifty patients were recruited in this study (mizoribine plus MTX group: n=35, mizoribine group: n=15). There were no significant differences in the initial laboratory values between the two treatment groups. After treatment for 16 weeks, the DAS28 was decreased significantly in the mizoribine plus MTX group (4.7±1.14 vs. 3.9±0.97, respectively, p<0.05). Yet the mizoribine alone group did not showed any significant change of the DAS28 (4.3±0.56 vs. 3.9±0.37, respectively, p=0.076). Mild gastrointestinal disturbance was the most common adverse effect. The incidence of adverse effects was similar in both treatment groups (20% vs. 27%, respectively). Conclusions: Mizoribine in combination with MTX was effective for RA patients who showed an ineffective response or intolerance to MTX. Furthermore, this treatment can be considered to be relatively safe.(Korean J Med 73:192-199, 2007)

참고문헌 (Reference)

1 Anderson PA, "Weekly pulse methotrexate in rheumatoid arthritis: clinical and immunologic effects in a randomized double-blind study" 103 : 489-496, 1985

2 Blass S, "The immunologic homunculus in rheumatoid arthritis" 42 : 2499-2506, 1999

3 Sakai K, "Synovial fluid and plasma levels of mizoribine in RA patients" 14 : 521-524, 1994

4 Amemiya H, "Synergistic effect of cyclosporine and mizoribine on survival of dog renal allografts" 46 : 768-771, 1988

5 Mizuno K, "Studies on bredinin: I. isolation, characterization and biological properties" 27 : 775-782, 1974

6 Harris ED, "Rheumatoid arthritis: pathophysiology and implications for therapy" 322 : 1277-1289, 1990

7 Prevoo ML, "Modified disease activity scores that include twenty- eight-joint counts: development and validation in a prospective longitudinal study of patients with rheumatoid arthritis" 38 : 44-48, 1995

8 Yokota S, "Mizoribine: mode of action and effects in clinical use" 44 : 196-198, 2002

9 Takei S, "Mizoribine in the treatment of rheumatoid arthritis and juvenile idiopathic arthritis" 44 : 205-209, 2002

10 Alarcon GS, "Lack of association between HLADR2 and clinical response to methotrexate in patients with rheumatoid arthritis" 30 : 218-220, 1987

11 Drosos AA, "Influence of methotrexate on radiographic progression in rheumatoid arthritis: a sixty-month prospective study" 15 : 263-267, 1997

12 Yoshizawa M, "Immunosuppressive effect of mizoribine: II. suppression of humoral and cellular immune response" 14 : 561-570, 1982

13 Yoshizawa M, "Immunosuppressive effect of mizoribine: I. effect on immune response cells" 14 : 256-262, 1982

14 Kamata K, "Immunosuppressive effect of bredinin on cell-mediated and humoral immune reactions in experimental animals" 35 : 144-149, 1983

15 Kusaba R, "Immunosuppressive effect of bredinin in the management of patients with renal transplantation" 18 : 420-425, 1981

16 Weinblatt ME, "Efficacy of low-dose methotrexate in rheumatoid arthritis" 312 : 818-822, 1985

17 Dayton JS, "Comparison of the effects of mizoribine with those of azathioprine, 6-mercaptopurine, and mycophenolic acid on T lymphocyte proliferation and purine ribonu-cleotide metabolism" 41 : 671-676, 1992

18 Williams HJ, "Comparison of low-dose oral pulse methotrexate and placebo in the treatment of rheumatoid arthritis: a controlled clinical trial" 28 : 721-730, 1985

19 Pincus T, "Combination therapy with multiple disease-modifying antirheumatic drugs in rheumatoid arthritis: a preventive strategy" 131 : 768-774, 1999

20 Furst DE, "Adverse experience with methotrexate during 176 weeks of a longterm prospective trial in patients with rheumatoid arthritis" 17 : 1628-1635, 1990